22.58

0.40% 0.09

After Hours: 22.53 -0.05 -0.22%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $22.58, with a volume of 3.53M. It is up +0.40% in the last 24 hours and down -18.98% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$22.49

Open:

$22.95

24h Volume:

3.53M

Relative Volume:

3.03

Market Cap:

$2.70B

Revenue:

$22.57M

Net Income/Loss:

$-212.73M

P/E Ratio:

-12.51

EPS:

-1.8045

Net Cash Flow:

$-142.19M

1W Performance:

+0.98%

1M Performance:

-18.98%

6M Performance:

-21.98%

1Y Performance:

-15.40%

1-Day Range:

$21.68

$23.20

1-Week Range:

$21.02

$23.20

52-Week Range:

$21.02

$42.20

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1069)

Industry

Biotechnology (596)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	22.58	2.73B	22.57M	-212.73M	-142.19M	-1.8045
VRTX Vertex Pharmaceuticals Inc	510.72	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	798.17	80.46B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	172.94	57.48B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	988.20	61.58B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	365.67	39.20B	5.76B	514.49M	1.10B	4.4813

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Sep 12, 2026

Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily

Sep 12, 2026

Sep 10, 2026

NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com

Sep 10, 2026

NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK

Sep 10, 2026

Sep 09, 2026

Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com Nigeria

Sep 09, 2026

NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK

Sep 09, 2026

NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan

Sep 09, 2026

Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com

Sep 09, 2026

Sep 08, 2026

NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha

Sep 08, 2026

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria

Sep 08, 2026

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com

Sep 08, 2026

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Sep 08, 2026

Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView

Sep 08, 2026

Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Sep 08, 2026

Sep 07, 2026

NewAmsterdam Pharma Company N.V. - Reuters

Sep 07, 2026

Sep 03, 2026

NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - Kalkine Media

Sep 03, 2026

NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan

Sep 03, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 03, 2026

NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn

Sep 03, 2026

Sep 02, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times

Sep 02, 2026

Aug 28, 2026